Site-specific Antibody-polymer Conjugates for SiRNA Delivery

Overview

Journal J Am Chem Soc

Publisher American Chemical Society

Specialty Chemistry

Date 2013 Aug 9

PMID 23924037

Citations 29

Authors

Hua Lu

Danling Wang

Stephanie Kazane

Tsotne Javahishvili

Feng Tian

Frank Song

Aaron Sellers

Barney Barnett

Peter G Schultz

Affiliations

Soon will be listed here.

Abstract

We describe here the development of site-specific antibody-polymer conjugates (APCs) for the selective delivery of small interference RNAs (siRNAs) to target cells. APCs were synthesized in good yields by conjugating an aminooxy-derivatized cationic block copolymer to an anti-HER2 Fab or full-length IgG by means of genetically encoded p-acetyl phenylalanine (pAcF). The APCs all showed binding affinity comparable to that of HER2 as their native counterparts and no significant cellular cytotoxicity. Mutant S202-pAcF Fab and Q389-pAcF IgG polymer conjugates specifically delivered siRNAs to HER2(+) cells and mediated potent gene silencing at both the mRNA and protein levels. However, a mutant A121-pAcF IgG polymer conjugate, despite its high binding affinity to HER2 antigen, did not induce a significant RNA interference response in HER2(+) cells, presumably due to steric interference with antigen binding and internalization. These results highlight the importance of conjugation site on the activity of antibody-polymer-based therapeutics and suggest that such chemically defined APCs may afford a useful targeted delivery platform for siRNAs or other nucleic acid-based therapies.

Citing Articles

Advancing Therapeutic Strategies with Polymeric Drug Conjugates for Nucleic Acid Delivery and Treatment.

Ullah A, Khan M, Zhang Y, Shafiq M, Ullah M, Abbas A Int J Nanomedicine. 2025; 20():25-52.

PMID: 39802382 PMC: 11717654. DOI: 10.2147/IJN.S429279.

Biosynthesis of Halogenated Tryptophans for Protein Engineering Using Genetic Code Expansion.

Guo Y, Cheng L, Hu Y, Zhang M, Liu R, Wang Y Chembiochem. 2024; 25(20):e202400366.

PMID: 38958600 PMC: 11483216. DOI: 10.1002/cbic.202400366.

Applications of genetic code expansion technology in eukaryotes.

Guo Q, Cao Y Protein Cell. 2023; 15(5):331-363.

PMID: 37847216 PMC: 11074999. DOI: 10.1093/procel/pwad051.

Site-Specific Antibody Conjugation with Payloads beyond Cytotoxins.

Zhou Q Molecules. 2023; 28(3).

PMID: 36770585 PMC: 9921355. DOI: 10.3390/molecules28030917.

Biopolymer-Based Nanosystems for siRNA Drug Delivery to Solid Tumors including Breast Cancer.

Subhan M, Torchilin V Pharmaceutics. 2023; 15(1).

PMID: 36678782 PMC: 9861964. DOI: 10.3390/pharmaceutics15010153.

References

Lee J, Yun K, Choi C, Shin S, Ban H, Rhim T . T cell-specific siRNA delivery using antibody-conjugated chitosan nanoparticles. Bioconjug Chem. 2012; 23(6):1174-80. DOI: 10.1021/bc2006219. View

Dassie J, Liu X, Thomas G, Whitaker R, Thiel K, Stockdale K . Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol. 2009; 27(9):839-49. PMC: 2791695. DOI: 10.1038/nbt.1560. View

Jeong J, Mok H, Oh Y, Park T . siRNA conjugate delivery systems. Bioconjug Chem. 2008; 20(1):5-14. DOI: 10.1021/bc800278e. View

Wu X, Schultz P . Synthesis at the interface of chemistry and biology. J Am Chem Soc. 2009; 131(35):12497-515. PMC: 5847295. DOI: 10.1021/ja9026067. View

Peer D, Park E, Morishita Y, Carman C, Shimaoka M . Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science. 2008; 319(5863):627-30. PMC: 2490797. DOI: 10.1126/science.1149859. View

Hutchins B, Kazane S, Staflin K, Forsyth J, Felding-Habermann B, Schultz P . Site-specific coupling and sterically controlled formation of multimeric antibody fab fragments with unnatural amino acids. J Mol Biol. 2011; 406(4):595-603. PMC: 4278757. DOI: 10.1016/j.jmb.2011.01.011. View

Kim C, Axup J, Dubrovska A, Kazane S, Hutchins B, Wold E . Synthesis of bispecific antibodies using genetically encoded unnatural amino acids. J Am Chem Soc. 2012; 134(24):9918-21. PMC: 4299457. DOI: 10.1021/ja303904e. View

Luedtke N, Carmichael P, Tor Y . Cellular uptake of aminoglycosides, guanidinoglycosides, and poly-arginine. J Am Chem Soc. 2003; 125(41):12374-5. DOI: 10.1021/ja0360135. View

Zimmermann T, Lee A, Akinc A, Bramlage B, Bumcrot D, Fedoruk M . RNAi-mediated gene silencing in non-human primates. Nature. 2006; 441(7089):111-4. DOI: 10.1038/nature04688. View

10.

Kumar P, Ban H, Kim S, Wu H, Pearson T, Greiner D . T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell. 2008; 134(4):577-86. PMC: 2943428. DOI: 10.1016/j.cell.2008.06.034. View

11.

Lee H, Lytton-Jean A, Chen Y, Love K, Park A, Karagiannis E . Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat Nanotechnol. 2012; 7(6):389-93. PMC: 3898745. DOI: 10.1038/nnano.2012.73. View

12.

Bennett C, Swayze E . RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol. 2010; 50:259-93. DOI: 10.1146/annurev.pharmtox.010909.105654. View

13.

Peer D, Zhu P, Carman C, Lieberman J, Shimaoka M . Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci U S A. 2007; 104(10):4095-100. PMC: 1820714. DOI: 10.1073/pnas.0608491104. View

14.

McNamara 2nd J, Andrechek E, Wang Y, Viles K, Rempel R, Gilboa E . Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol. 2006; 24(8):1005-15. DOI: 10.1038/nbt1223. View

15.

Thomas M, Kularatne S, Qi L, Kleindl P, Leamon C, Hansen M . Ligand-targeted delivery of small interfering RNAs to malignant cells and tissues. Ann N Y Acad Sci. 2009; 1175:32-9. DOI: 10.1111/j.1749-6632.2009.04977.x. View

16.

Zhang K, Hao L, Hurst S, Mirkin C . Antibody-linked spherical nucleic acids for cellular targeting. J Am Chem Soc. 2012; 134(40):16488-91. PMC: 3501255. DOI: 10.1021/ja306854d. View

17.

Yu D, Pendergraff H, Liu J, Kordasiewicz H, Cleveland D, Swayze E . Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell. 2012; 150(5):895-908. PMC: 3444165. DOI: 10.1016/j.cell.2012.08.002. View

18.

Sato Y, Murase K, Kato J, Kobune M, Sato T, Kawano Y . Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol. 2008; 26(4):431-42. DOI: 10.1038/nbt1396. View

19.

Peer D, Lieberman J . Special delivery: targeted therapy with small RNAs. Gene Ther. 2011; 18(12):1127-33. DOI: 10.1038/gt.2011.56. View

20.

Choi C, Alabi C, Webster P, Davis M . Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci U S A. 2010; 107(3):1235-40. PMC: 2824286. DOI: 10.1073/pnas.0914140107. View